DUBLIN, Oct. 29, 2024 (GLOBE NEWSWIRE) — “US Influenza Vaccines Market Report 2025: Industry Size, Market Share Data, Latest Trends, Insights, Growth Potential and CAGR Forecast to 2033” report published by ResearchAndMarkets added to. What com offers.
The U.S. influenza vaccine market has experienced significant growth in recent years due to a variety of factors, including increased public awareness of infectious diseases and continued innovation in vaccine technology.
As of 2024, the market value is estimated at approximately USD 4.78 billion, reflecting positive trends in terms of demand and accessibility. This growth is expected to continue, with the market likely to reach approximately USD 9.66 billion by 2033, at a compound annual growth rate (CAGR) of approximately 8% from 2025 to 2033. It is predicted to be equivalent.
The main driver of this upward trend is the increasing incidence of influenza and the resulting need for vaccination among diverse populations. The Centers for Disease Control and Prevention (CDC) emphasizes the importance of vaccination. Vaccination, coupled with government efforts to promote vaccine accessibility, is essential to maintaining public health standards. Additionally, advances in vaccine formulations, including the development of a quadrivalent vaccine that protects against four influenza strains, are expected to increase market attractiveness and further increase vaccination rates.
Additionally, in the United States, there has been an influx of new entrants into the influenza vaccine field in addition to traditional manufacturers, leading to increased competition and innovation. The industry landscape is increasingly being shaped by strategic partnerships and collaborations aimed at strengthening research and development capabilities. As more organizations become involved in influenza vaccine production, competition could lead to a greater variety of vaccine options available to consumers, thereby expanding the market.
Technological advances, particularly in the field of mRNA vaccines, are further changing the dynamics of vaccine development. The successful implementation of mRNA technology during the COVID-19 pandemic has opened an opportunity for a similar approach in the influenza vaccine field. These advances are expected to enhance immunogenicity and reduce the time required for vaccine development, thereby driving the market to grow at an accelerated pace in the coming years. Overall, the US influenza vaccine market is on an upward trend, strengthened by increased awareness, innovation, and strategic collaboration.
Latest trends in the US influenza vaccine market
The influenza vaccine market landscape is undergoing major changes due to various emerging trends. One of the most notable advances is in vaccine technology. Innovations such as mRNA technology, which were previously in the spotlight during the COVID-19 pandemic, are also gaining traction in the field of influenza vaccination. These advances are aimed at improving the effectiveness and speed of vaccine development and could lead to more effective annual vaccines tailored to evolving virus strains.
Another important trend is the increasing demand for personalized medicine in vaccine administration. Increasing understanding of genetic variation among individuals is leading to the development of personalized vaccines tailored to an individual’s immune profile. This customized approach not only maximizes the likelihood of an immune response but also minimizes potential side effects, thereby increasing overall vaccine uptake.
Public awareness is also changing, with increased acceptance of different vaccine formulations, including quadrivalent vaccines and high-dose vaccines. Raising awareness through public health campaigns and educational efforts has resulted in more people becoming more informed and willing to receive the influenza vaccine. However, challenges remain, including vaccine hesitancy caused by misinformation and skepticism over vaccine safety. It is important for health authorities and healthcare providers to address these concerns to increase vaccine acceptance.
In addition, factors such as age group and health status significantly influence vaccination propensity. The increasing number of elderly people and the increasing incidence of chronic diseases among young people create an urgent need for effective influenza prevention measures and emphasize the importance of vaccination. As research continues to uncover these trends, understanding them is critical for stakeholders looking to navigate the future landscape of the Influenza Vaccines market.
Competitive environment of the US influenza vaccine market
The U.S. influenza vaccine market is characterized by the presence of multiple major players, each contributing to the competitive landscape through their unique strategies and market share. Major manufacturers include prominent pharmaceutical companies such as GlaxoSmithKline, Sanofi Pasteur, AstraZeneca, and Sekyrus, which together control a significant portion of the market.
Competitive strategies adopted by manufacturers, such as pricing models, promotional activities, and collaboration with healthcare institutions, help shape the dynamics of the US influenza vaccine market.
Report scope
US Influenza Vaccine Market: Size, Insights, Analysis, and Forecasts, Number and Forecast of People Vaccinated with Influenza Vaccines in the United States, 2019-2033, Analysis and Forecast of Children of Influenza Vaccines in the United States, 2019-2033 , 2019-2033 Adult Analysis US Influenza Vaccine Vaccines and Forecast 2019-2033 US Influenza Vaccine Market Key Growth Drivers and Challenges US Influenza Vaccine Price Analysis, Trends and Insights in the US Production, supply, and distribution of influenza vaccines (distribution and demand analysis of influenza vaccines in the United States Impact of vaccine efficacy and diagnosis Thorough evaluation of distribution channels and technology for influenza vaccines in the United States Reimbursement environment in the influenza vaccine market in the United States Influenza vaccines in the United States Regulatory overview of the market Key Influenza Vaccine market deals and agreements Insightful analysis of promising influenza vaccines in clinical development Examining the latest clinical trials of influenza vaccines Comprehensive list of key companies and current vaccine portfolio Analysis, Promising Vaccines in Clinical Development, Influenza Vaccines Market Value and Recent Developments Insightful analysis of emerging players along with analysis of promising vaccines in clinical development, stages, platform technologies, and recent developments
Profiles of top and up-and-coming players
Sanofi Pasteur GlaxoSmithKline (GSK) Seekyrus (CSL Limited) AstraZeneca Novavax Medicago Moderna Neumagen Daiichi Sankyo Ultimmune Fulgen Immutex Epivax Versatope Therapeutics Biondo Vax Pharmaceuticals Company
Key attributes:
Report Attribute Details No. Number of Pages 230 Forecast Period 2024 – 2033 Estimated Market Value in 2024 (USD) 4.78 billion USD Predicted Market Value by 2033 (USD) 9.66 Billion USD Average Annual Growth Rate 8.0% Target area: United States
Main topics covered:
1. Introduction
2. Research method
3. Summary
4. US Influenza Vaccine Market Size, Insights, Analysis and Forecast (2019 – 2033)
5. Number of people vaccinated with influenza vaccine in the United States (2019-2033)
5.1 Number of children vaccinated with influenza vaccine
5.2 Number of adults vaccinated with influenza vaccine
6. Key market growth drivers and challenges of the US influenza vaccine market
6.1 Market drivers
6.2 Market challenges
7. US Flu Vaccine Price Analysis, Trends, and Insights
8. U.S. Influenza Vaccine Production, Supply, and Allocation by Company, 2014-2024
9. US Influenza Vaccine Distribution and Demand Analysis 2010-2024
10. Influenza vaccine effectiveness in the United States, 2004-2024
11. Rapid diagnostic tests for influenza management
12. Detailed Insights into Distribution Channels and Technologies for Influenza Vaccination in the United States
13. US Influenza Vaccine Market Reimbursement Environment
14. Regulatory Framework for the US Influenza Vaccine Market
15. Major trading and contracting activities in the influenza vaccine market
15.1 Mergers and Acquisitions
15.2 Collaboration Transactions
15.3 License Agreement
15.4 Exclusive Agreement
15.5 Sales Agreement
16. Promising influenza vaccines in clinical development
17. Influenza Vaccine Clinical Trial Insights by Phase, Company, and Country
17.1 2024
17.2 2023
17.3 2022
17.4 2021
18. Main company overview
18.1 Sanofi Pasteur
18.1.1 Business overview
18.1.2 Influenza vaccine portfolio
18.1.3 Influenza vaccine sales analysis
18.1.4 Promising influenza vaccines in clinical development
18.1.5 Recent Developments
18.2 GlaxoSmithKline (GSK)
18.3 Sekyrus
18.4 AstraZeneca
19. Overview of emerging companies
19.1 Novavax
19.1.1 Business overview
19.1.2 Promising influenza vaccines in clinical development
19.1.3 Recent Developments
19.2 BiondVax Pharmaceutical Co., Ltd.
19.3 Medicago
19.4 Moderna Inc.
19.5 Pneumagen
19.6 Ultimune
19.7 Daiichi Sankyo
19.8 Fulgen
19.9 Eye Mutex
19.10 Epivax
19.11 Versatope Therapeutics, Inc.
For more information on this report, please visit https://www.researchandmarkets.com/r/iu4j3v.
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source of international market research reports and market data. We provide the latest data on international and regional markets, key industries, top companies, new products and latest trends.
US influenza vaccine market
